KN056 / Alphamab - LARVOL DELTA

A phase 1, randomized, double-blind, placebo-controlled trial investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of KN056 (a recombinant human GLP-1 variant Fc fusion protein) in healthy Chinese participants. (PubMed, Expert Opin Investig Drugs) - "Body weight decreased within seven days of administration, correlating with dose levels, with a mean reduction of -1.68 kg in the 12.0 mg group; however, no significant change in body weight was observed by the end of the study. KN056 demonstrated favorable PK, PD, and safety profiles in healthy Chinese participants, supporting its potential for once-weekly dosing."

Clinical • Journal • P1 data • PK/PD data • Diabetes • Gastrointestinal Disorder • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study to Evaluate Effects of KN056 in Healthy Participants (clinicaltrials.gov) - P1 | N=46 | Completed | Sponsor: Suzhou Alphamab Co., Ltd. | Recruiting ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study to Evaluate Effects of KN056 in Healthy Participants (clinicaltrials.gov) - P1 | N=46 | Recruiting | Sponsor: Suzhou Alphamab Co., Ltd. | Trial completion date: Aug 2023 ➔ Apr 2024 | Trial primary completion date: Jul 2023 ➔ Nov 2023

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study to Evaluate Effects of KN056 in Healthy Participants (clinicaltrials.gov) - P1 | N=38 | Recruiting | Sponsor: Suzhou Alphamab Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial primary completion date: Jan 2023 ➔ Jul 2023

Enrollment open • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

A Study to Evaluate Effects of KN056 in Healthy Subjects (clinicaltrials.gov) - P1 | N=38 | Not yet recruiting | Sponsor: Suzhou Alphamab Co., Ltd.

New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus